{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "3C-like protease (3CL(pro))",
      "Coronaviruses",
      "Papain-like protease (PL(pro))",
      "RNA-dependent RNA polymerase (RdRp)",
      "SARS-CoV-2",
      "Transmembrane serine protease (TMPRSS2)"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33556871",
  "DateCompleted": {
    "Year": "2021",
    "Month": "04",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "02",
        "Day": "03"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.biopha.2021.111313",
      "S0753-3322(21)00098-6"
    ],
    "Journal": {
      "ISSN": "1950-6007",
      "JournalIssue": {
        "Volume": "137",
        "PubDate": {
          "Year": "2021",
          "Month": "May"
        }
      },
      "Title": "Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie",
      "ISOAbbreviation": "Biomed Pharmacother"
    },
    "ArticleTitle": "An update review of emerging small-molecule therapeutic options for COVID-19.",
    "Pagination": {
      "StartPage": "111313",
      "MedlinePgn": "111313"
    },
    "Abstract": {
      "AbstractText": [
        "The SARS-CoV-2 outbreak and pandemic that began near the end of 2019 has posed a challenge to global health. At present, many candidate small-molecule therapeutics have been developed that can inhibit both the infection and replication of SARS-CoV-2 and even potentially relieve cytokine storms and other related complications. Meanwhile, host-targeted drugs that inhibit cellular transmembrane serine protease (TMPRSS2) can prevent SARS-CoV-2 from entering cells, and its combination with chloroquine and dihydroorotate dehydrogenase (DHODH) inhibitors can limit the spread of SARS-CoV-2 and reduce the morbidity and mortality of patients with COVID-19. The present article provides an overview of these small-molecule therapeutics based on insights from medicinal chemistry research and focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as the nucleoside analogues remdesivir, favipiravir and ribavirin. This review also covers inhibitors of 3C-like protease (3CL<sup>pro</sup>), papain-like protease (PL<sup>pro</sup>) and other potentially innovative active ingredient molecules, describing their potential targets, activities, clinical status and side effects."
      ],
      "CopyrightInformation": "Copyright \u00a9 2021 The Author(s). Published by Elsevier Masson SAS.. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Life Sciences, Jilin University, Changchun, 130012, PR China."
          }
        ],
        "LastName": "Tian",
        "ForeName": "Dengke",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an, 710021, PR China."
          }
        ],
        "LastName": "Liu",
        "ForeName": "Yuzhi",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Life Sciences, Jilin University, Changchun, 130012, PR China; Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an, 710021, PR China. Electronic address: chengyuanliang@gmail.com."
          }
        ],
        "LastName": "Liang",
        "ForeName": "Chengyuan",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an, 710021, PR China."
          }
        ],
        "LastName": "Xin",
        "ForeName": "Liang",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Shaanxi Panlong Pharmaceutical Group Co., Ltd., Xi'an, 710025, PR China."
          }
        ],
        "LastName": "Xie",
        "ForeName": "Xiaolin",
        "Initials": "X"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Shaanxi Panlong Pharmaceutical Group Co., Ltd., Xi'an, 710025, PR China."
          }
        ],
        "LastName": "Zhang",
        "ForeName": "Dezhu",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Medicine and Pharmacy, Shaanxi University of Business & Commerce, Xi'an 712046, PR China."
          }
        ],
        "LastName": "Wan",
        "ForeName": "Minge",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an, 710021, PR China."
          }
        ],
        "LastName": "Li",
        "ForeName": "Han",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "School of Life Sciences, Jilin University, Changchun, 130012, PR China."
          }
        ],
        "LastName": "Fu",
        "ForeName": "Xueqi",
        "Initials": "X"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai, 519030, PR China. Electronic address: sesource_liuhong@163.com."
          }
        ],
        "LastName": "Liu",
        "ForeName": "Hong",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai, 519030, PR China. Electronic address: sesource_cwq@163.com."
          }
        ],
        "LastName": "Cao",
        "ForeName": "Wenqiang",
        "Initials": "W"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Biomed Pharmacother",
    "NlmUniqueID": "8213295",
    "ISSNLinking": "0753-3322"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Enzyme Inhibitors"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "classification",
        "pharmacology"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Enzyme Inhibitors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "methods"
      ],
      "DescriptorName": "Molecular Targeted Therapy"
    },
    {
      "QualifierName": [
        "drug effects",
        "enzymology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Therapies, Investigational"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "The authors declared that they have no conflicts of interest to this work."
}